Ainos Inc(AIMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.53 | Insider Own | 75.2% | Shs Outstand | 7.4M | Perf Week | -20.77% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -3.27% | Shs Float | 1.8M | Perf Month | -54.18% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 2.34% | Short Float | 2.57% | Perf Quarter | -56.03% |
| Income | -0.01B | P/S | 457.65 | EPS this Y | - | Inst Trans | 8.63% | Short Ratio | 0.25 | Perf Half Y | -63.74% |
| Sales | 0.00B | P/B | 1.39 | EPS next 5Y | - | ROA | -66.48% | Short Interest | 0.05M | Perf YTD | -62.2% |
| Book/sh | 0.44 | P/C | 3.22 | EPS past 3/5Y | 48.74% 23.68% | ROE | -196.3% | 52W High | -84.02% ($3.88) | Perf Year | -81.21% |
| Cash/sh | 0.19 | P/FCF | - | Sales past 3/5Y | -67.2% 49.61% | ROIC | -440.15% | 52W Low | 10.69% ($0.56) | Perf 3Y | -95.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 51.12% | Gross Margin | -34987.54% | Volatility(W/M) | 15.29% 11.56% | Perf 5Y | -99.77% |
| Dividend TTM | - | EV/Sales | 1696.65 | Sales Y/Y TTM | -87.73% | Oper. Margin | -101210.17% | ATR (14) | 0.11 | Perf 10Y | -99.44% |
| Dividend Ex-Date | - | Quick Ratio | 0.12 | EPS Q/Q | 36.98% | Profit Margin | -106283.32% | RSI (14) | 15.22 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.13 | Sales Q/Q | -96.74% | SMA20 | -33.93% ($0.94) | Beta | 2.67 | Target Price | - |
| Payout | - | Debt/Eq | 4.21 | Earnings | - | SMA50 | -49.33% ($1.22) | Rel Volume | 0.13 | Prev Close | $0.63 |
| Employees | 41 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -60.97% ($1.59) | Avg Volume(3M) | 0.19M | Price | $0.62 |
| IPO | 1996/8/8 | Option/Short | No/Yes | Trades | 95 | Volume | 23,502 | Change | -1.37% |
Ainos Inc. (AIND) is a hybrid public company built around two main pillars: the "AI Nose" smell-digitization platform and the low-dose oral interferon therapeutic VELDONA. AI Nose targets hygiene and quality monitoring applications such as senior care, robotics, and semiconductor manufacturing, while VELDONA continues its development as an orphan-drug-designated treatment for indications including oral warts in HIV patients.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 13% of its average volume.
AIMD has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $45,765. Peers typically go for $511.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #30 of 32 in the industry
Based on market cap of $5M.
FAQ
What kind of company is AIMD?
AIMD belongs to the Technology sector and operates in the Scientific & Technical Instruments industry.
What is the market cap of AIMD?
The market cap of AIMD is approximately $5M, ranking 5,637 within its sector.
What is the 52-week high and low for AIMD?
AIMD has recorded a 52-week high of $3.88 and a low of $0.56.
